Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform
暂无分享,去创建一个
Alessandro Aiuti | Andrea Calabria | Fabrizio Benedicenti | Erika Tenderini | Eugenio Montini | Andrea Biondi | A. Aiuti | L. Cooper | A. Biondi | F. Benedicenti | E. Montini | Laurence J.N. Cooper | E. Biagi | A. Calabria | Chiara F. Magnani | Nice Turazzi | Sarah Tettamanti | Greta M.P. Giordano Attianese | Ettore Biagi | S. Tettamanti | G. G. Attianese | N. Turazzi | E. Tenderini
[1] C. Coch,et al. Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC) , 2015, Journal of Cancer Research and Clinical Oncology.
[2] A. Field,et al. Comparison of Lentiviral and Sleeping Beauty Mediated αβ T Cell Receptor Gene Transfer , 2013, PloS one.
[3] Wei Chen,et al. Genome-wide Profiling Reveals Remarkable Parallels Between Insertion Site Selection Properties of the MLV Retrovirus and the piggyBac Transposon in Primary Human CD4+ T Cells , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.
[4] Luca Biasco,et al. Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome , 2013, Science.
[5] H. Heslop,et al. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[6] A. Bagg,et al. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. , 2015, The New England journal of medicine.
[7] H. Abken,et al. Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation". , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[8] Daniel F Voytas,et al. Common physical properties of DNA affecting target site selection of sleeping beauty and other Tc1/mariner transposable elements. , 2002, Journal of molecular biology.
[9] Cory Y. McLean,et al. GREAT improves functional interpretation of cis-regulatory regions , 2010, Nature Biotechnology.
[10] D. Powell,et al. Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor , 2015, Oncotarget.
[11] Clelia Di Serio,et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells , 2013, Nature Medicine.
[12] T. Barbui,et al. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. , 2007, Haematologica.
[13] Sadik H. Kassim,et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Luigi Naldini,et al. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics , 2001, Nature Medicine.
[15] Hanno Glimm,et al. High-resolution insertion-site analysis by linear amplification–mediated PCR (LAM-PCR) , 2007, Nature Methods.
[16] Bernd Hauck,et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.
[17] S. Olivares,et al. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. , 2011, Cancer research.
[19] G. Calin,et al. Progresses towards safe and efficient gene therapy vectors , 2015, Oncotarget.
[20] A. Biondi,et al. Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy. , 2006, Experimental hematology.
[21] Qing He,et al. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.
[22] A. Scott,et al. Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma. , 1997, Molecular immunology.
[23] Angel F. Lopez,et al. Targeting of acute myeloid leukaemia by cytokine‐induced killer cells redirected with a novel CD123‐specific chimeric antigen receptor , 2013, British journal of haematology.
[24] E. Shpall,et al. System Sleeping Beauty the Redirecting Specificity of T-cell Populations for Cd19 Using Cited Articles Citing Articles E-mail Alerts Redirecting Specificity of T-cell Populations for Cd19 Using the Sleeping Beauty System , 2022 .
[25] A. Biondi,et al. Advanced Targeted, Cell and Gene-Therapy Approaches for Pediatric Hematological Malignancies: Results and Future Perspectives , 2013, Front. Oncol..
[26] J. Wagner,et al. Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[27] Pamela A Shaw,et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.
[28] C. Creighton,et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. , 2014, Blood.
[29] Alistair G. Rust,et al. Chromatin Landscapes of Retroviral and Transposon Integration Profiles , 2014, PLoS genetics.
[30] A. Biondi,et al. Donor-derived CD19-targeted T cells in allogeneic transplants , 2015, Current opinion in hematology.
[31] J. Tolar,et al. Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system. , 2005, Blood.
[32] R. Negrin,et al. In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. , 2008, Blood.
[33] Z. Eshhar,et al. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[34] H. Abken,et al. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+ T cells , 2012, Oncoimmunology.
[35] Christof von Kalle,et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. , 2009, The Journal of clinical investigation.
[36] F. Marincola,et al. A human memory T-cell subset with stem cell-like properties , 2011, Nature Medicine.
[37] C. Rooney,et al. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[38] B. Levine,et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. , 2010, Cancer research.
[39] I. Weissman,et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity , 1991, The Journal of experimental medicine.
[40] F. Bushman,et al. Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells , 2012, Science Translational Medicine.
[41] Shawn M. Burgess,et al. High-Resolution Genome-Wide Mapping of Transposon Integration in Mammals , 2005, Molecular and Cellular Biology.
[42] D. Bonnet,et al. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo , 2014, Leukemia.
[43] W. Han,et al. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis , 2015, Oncotarget.
[44] S. Olivares,et al. Manufacture of Clinical-Grade CD19-Specific T Cells Stably Expressing Chimeric Antigen Receptor Using Sleeping Beauty System and Artificial Antigen Presenting Cells , 2013, PloS one.
[45] C. von Kalle,et al. Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy , 2013, Science.
[46] R. Plasterk,et al. Molecular Reconstruction of Sleeping Beauty , a Tc1-like Transposon from Fish, and Its Transposition in Human Cells , 1997, Cell.
[47] A Orfao,et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). , 1995, Leukemia.
[48] S. Rosenberg,et al. Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity , 2009, Gene Therapy.
[49] Seth M Steinberg,et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.
[50] A. Lawson,et al. Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors , 2010, Haematologica.
[51] David L. Porter,et al. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.
[52] S. Ekker,et al. Gene transfer efficiency and genome-wide integration profiling of Sleeping Beauty, Tol2, and piggyBac transposons in human primary T cells. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.